GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » EPS (Diluted)

Relypsa (Relypsa) EPS (Diluted) : $-5.77 (TTM As of Jun. 2016)


View and export this data going back to 2013. Start your Free Trial

What is Relypsa EPS (Diluted)?

Relypsa's Earnings per Share (Diluted) for the three months ended in Jun. 2016 was $-1.87. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 was $-5.77.

Relypsa's EPS (Basic) for the three months ended in Jun. 2016 was $-1.87. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2016 was $-5.77.

Relypsa's EPS without NRI for the three months ended in Jun. 2016 was $-1.87. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2016 was $-5.77.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Relypsa EPS (Diluted) Historical Data

The historical data trend for Relypsa's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relypsa EPS (Diluted) Chart

Relypsa Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
EPS (Diluted)
- -4.51 -22.42 -2.43 -4.39

Relypsa Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.95 -1.24 -1.40 -1.26 -1.87

Competitive Comparison of Relypsa's EPS (Diluted)

For the Biotechnology subindustry, Relypsa's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relypsa's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relypsa's PE Ratio distribution charts can be found below:

* The bar in red indicates where Relypsa's PE Ratio falls into.



Relypsa EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Relypsa's Diluted EPS for the fiscal year that ended in Dec. 2015 is calculated as

Diluted EPS (A: Dec. 2015 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-178.716-0)/40.698
=-4.39

Relypsa's Diluted EPS for the quarter that ended in Jun. 2016 is calculated as

Diluted EPS (Q: Jun. 2016 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-83.616-0)/44.768
=-1.87

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relypsa  (NAS:RLYP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Relypsa EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Relypsa's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Relypsa (Relypsa) Business Description

Traded in Other Exchanges
N/A
Address
Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Executives
Ronald A. Krasnow officer: See Remarks C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball officer: Chief Financial Officer & SVP C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J director 33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings director 61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl officer: SVP, Chief Technology Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland officer: SVP & Chief Commercial Officer 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley director C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi 10-26-2015